Epigenomics AG | |
Stock Exchange | Other OTC |
EPS |
$0.48 |
Market Cap |
$73.66 M |
Shares Outstanding |
24.01 M |
Public Float |
- |
Epigenomics AG | |
Stock Exchange | Xetra Stock Exchange |
EPS |
EUR0.41 |
Market Cap |
EUR65.56 M |
Shares Outstanding |
36.02 M |
Public Float |
25.65 M |
Address |
Geneststraße 5 Berlin Berlin 10829 Germany |
Employees | - |
Website | http://www.epigenomics.de |
Updated | 07/08/2019 |
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, and Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA. The comapny was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo Gut on April 30, 1997 and is headquartered in Berlin, Germany. |